Biomea Fusion is highlighting the science behind diabetes treatment as it pushes for new therapeutic approaches. The effort follows Phase II data on icovamenib

Biomea Fusion is highlighting the science behind diabetes treatment as it pushes for new therapeutic approaches. The effort follows Phase II data on icovamenib in type 1 diabetes and prior trial results showing HbA1c improvement beyond 12 weeks.